Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
denosumab + etanercept
- Development stage
- Preclinical
- Lead developer
- Amgen
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
A combination therapy consisting of denosumab, a fully human monoclonal antibody that targets RANKL to inhibit bone resorption, and etanercept, a TNF inhibitor used to treat inflammatory conditions. This dual biologic therapy is used primarily in patients with rheumatoid arthritis and other inflammatory rheumatic diseases who also have osteoporosis or are at risk for bone loss.
02
Targets
RANKL (Receptor Activator for Nuclear Factor-kappa B Ligand)TNFA (Tumor necrosis factor alpha (soluble))LTA (Lymphotoxin-alpha)
Beyond the preview
Go deeper on denosumab + etanercept.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on denosumab + etanercept.